KR20030048082A - 플라그 및 결석의 감소를 위해 해초를 함유하는 구강 제제 - Google Patents
플라그 및 결석의 감소를 위해 해초를 함유하는 구강 제제 Download PDFInfo
- Publication number
- KR20030048082A KR20030048082A KR10-2003-7005794A KR20037005794A KR20030048082A KR 20030048082 A KR20030048082 A KR 20030048082A KR 20037005794 A KR20037005794 A KR 20037005794A KR 20030048082 A KR20030048082 A KR 20030048082A
- Authority
- KR
- South Korea
- Prior art keywords
- seaweed
- stones
- plaques
- plaque
- extract
- Prior art date
Links
- 241001474374 Blennius Species 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000004575 stone Substances 0.000 claims abstract description 32
- 239000000284 extract Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 241000512260 Ascophyllum Species 0.000 claims abstract description 13
- MSXHSNHNTORCAW-MPGIDXPLSA-M sodium;(3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].O[C@@H]1OC(C([O-])=O)[C@@H](O)[C@H](O)[C@@H]1O MSXHSNHNTORCAW-MPGIDXPLSA-M 0.000 claims abstract description 13
- 241000512259 Ascophyllum nodosum Species 0.000 claims abstract description 10
- 238000009472 formulation Methods 0.000 claims abstract description 10
- 241000124008 Mammalia Species 0.000 claims abstract description 9
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims abstract description 8
- 208000000913 Kidney Calculi Diseases 0.000 claims abstract description 6
- 206010029148 Nephrolithiasis Diseases 0.000 claims abstract description 6
- 241000282472 Canis lupus familiaris Species 0.000 claims abstract description 5
- 241000282412 Homo Species 0.000 claims abstract description 5
- 230000001580 bacterial effect Effects 0.000 claims abstract description 5
- 241000282326 Felis catus Species 0.000 claims abstract description 4
- 201000001883 cholelithiasis Diseases 0.000 claims abstract description 4
- 208000001130 gallstones Diseases 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 206010007019 Calculus prostatic Diseases 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229920001543 Laminarin Polymers 0.000 claims description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 3
- 229930003779 Vitamin B12 Natural products 0.000 claims description 3
- 229930003448 Vitamin K Natural products 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 150000001746 carotenes Chemical class 0.000 claims description 3
- 235000005473 carotenes Nutrition 0.000 claims description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 235000019157 thiamine Nutrition 0.000 claims description 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 3
- 229960003495 thiamine Drugs 0.000 claims description 3
- 239000011721 thiamine Substances 0.000 claims description 3
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims description 3
- 235000019163 vitamin B12 Nutrition 0.000 claims description 3
- 239000011715 vitamin B12 Substances 0.000 claims description 3
- 235000019168 vitamin K Nutrition 0.000 claims description 3
- 239000011712 vitamin K Substances 0.000 claims description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 3
- 229940046010 vitamin k Drugs 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 208000006558 Dental Calculus Diseases 0.000 abstract description 15
- 230000000069 prophylactic effect Effects 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 208000008494 pericarditis Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 230000009979 protective mechanism Effects 0.000 description 2
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000220259 Raphanus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 206010044029 Tooth deposit Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Birds (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
- Endoscopes (AREA)
Abstract
Description
물 | 12-15% |
회 | 17-20% |
알긴산 | 20-26% |
마니톨 | 5-8% |
라미나란 | 2-5% |
화이버 | <8% |
단백질 | 5-10% |
에테르 추출물 | 2-4% |
푸코이딘 | 10% |
S | 2.5-3.5% |
K | 2-3% |
Cl | 3.1-4.4% |
Na | 3-4% |
Mg | 0.5-0.9% |
Ca | 1-3% |
P | 0.1-0.15% |
Br | 40-100mg/kg |
Co | 1-10mg/kg |
Cu | 1-10mg/kg |
Fe | 150-1000mg/kg |
Mn | 10-50mg/kg |
I | 700-1200mg/kg |
Zn | 20-200mg/kg |
Mo | 0.3-1mg/kg |
Ni | 2-5mg/kg |
Ba | 15-50mg/kg |
V | 1.5-3mg/kg |
아스코브르산 | 500-2000mg/kg |
토코페롤 | 150-300mg/kg |
카로틴 | 30-60mg/kg |
니아신 | 10-30mg/kg |
비오틴 | 0.1-0.4mg/kg |
엽산 | 0.2-1mg/kg |
리보플라빈 | 5-10mg/kg |
티아민 | 1-5mg/kg |
비타민 B12 | 0.004mg/kg |
비타민 K | 10mg/kg |
Claims (10)
- 포유류 플라그 및/또는 결석의 감소를 위한 구강 제제의 제조에 사용하기 위한 아스코필럼 에스피(Ascophyllum sp.) 해초 또는 그 추출물.
- 제 1 항에 있어서, 포유류는 사람, 고양이 및 개중에 선택되는 것을 특징으로 하는 아스코필럼 에스피 해초 또는 그 추출물.
- 제 1 항 또는 제 2 항에 있어서, 구강 제제는 분말, 현탁물질, 정제, 코팅된 정제 및 캡슐중에서 선택되는 것을 특징으로 하는 아스코필럼 에스피 해초 또는 그 추출물.
- 제 1 항 내지 제 3 항중 어느 한 항에 있어서, 플라그는 세균성 플라그, 동맥 경화성 플라그, 죽상 경화성 플라그, 및 능막 플라그중에서 선택되며, 결석은 치석, 신장 결석, 담석, 및 정낭염(prostatic calculus)중에서 선택되는 것을 특징으로 하는 아스코필럼 에스피 해초 또는 그 추출물.
- 제 1 항 내지 제 4 항중 어느 한 항에 있어서, 해초는 아스코필럼 노도섬(Ascophyllum nodosum)인 것을 특징으로 하는 아스코필럼 에스피 해초 또는 그 추출물.
- 제 5 항에 있어서, Ascophyllum nodosum 해초는 하기의 분석된 화학 조성물:에스트르화 형태의 황하 우론산 20-26%, 마니톨 5-8%, 라미나란(Laminaran) 2-5%, 푸코이딘 5-15%, S 2.5-3.5%, K 2-3%, Cl 3-4%, Na 3-4%, Mg 0.5-1%, Ca 1-3%, P 0.1-0.15%, 및 Br 40-100mg/kg, Co 1-10mg, Cu 1-10mg, Fe 150-1000mg, Mn 10-50mg, I 700-1200mg, Zn 20-200mg, Mo 0.3-1mg, Ni 2-5mg, Ba 15-50mg, V 1.5-3mg 및 아스코르브산 500-2000mg, 코토페롤 150-300mg/kg, 캐로틴 30-60mg/kg, 니아신 10-30mg/kg, 비오틴 0.1-0.4mg/kg, 엽산 0.2-1mg/kg, 리보플라빈 5-10mg/kg, 티아민 1-5mg/kg, 비타민 B12 0.004mg/kg, 및 비타민 K 10mg/kg을 구비하는 것을 특징으로 하는 아스코필럼 에스피 해초 또는 그 추출물.
- 활성 성분으로서 포유류 플라그 및/또는 결석을 감소시키는Ascophyllum sp.해초 또는 그 추출물의 액을 포함하는 것을 특징으로 하는 단위 복용량(unite dose)의 구강 제제.
- 제 7 항에 있어서, 포유류 플라그 및/또는 결석을 감소시키는Ascophyllum sp.해초의 양은 단위 복용량 당 250mg-1g의 해초인 것을 특징으로 하는 단위 복용량의 구강 제제.
- 제 7 항 또는 제 8 항에 있어서,Ascophyllum sp.해초는Ascophyllumnosodum인 것을 특징으로 하는 단위 복용량의 구강 제제.
- 제 7 항 내지 제 9 항에 따라 포유류 개개에 단위 복용량의 구강 제제의 투여를 포함하여, 그 필요에 따라 포유류 개개의 플라그 및/또는 결석을 치료하는 예방 및/또는 치료 방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0003907-3 | 2000-10-27 | ||
SE0003907A SE0003907D0 (sv) | 2000-10-27 | 2000-10-27 | Komposition för eliminering av tandsten ur munnen |
PCT/SE2001/002083 WO2002034279A1 (en) | 2000-10-27 | 2001-09-27 | Oral preparation containing seaweed for reduction of plaque and calculus |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030048082A true KR20030048082A (ko) | 2003-06-18 |
KR100890723B1 KR100890723B1 (ko) | 2009-03-26 |
Family
ID=20281587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037005794A KR100890723B1 (ko) | 2000-10-27 | 2001-09-27 | 플라그 및 결석의 감소를 위한 해초를 함유하는 경구제제 |
Country Status (22)
Country | Link |
---|---|
US (1) | US7125555B2 (ko) |
EP (1) | EP1328285B1 (ko) |
JP (1) | JP4648611B2 (ko) |
KR (1) | KR100890723B1 (ko) |
CN (1) | CN1230195C (ko) |
AT (1) | ATE319463T1 (ko) |
AU (1) | AU2001290473A1 (ko) |
BR (1) | BRPI0114933B8 (ko) |
CA (1) | CA2426936C (ko) |
CY (1) | CY1105379T1 (ko) |
DE (1) | DE60117824T2 (ko) |
DK (1) | DK1328285T3 (ko) |
ES (1) | ES2260286T3 (ko) |
IS (1) | IS2288B (ko) |
MX (1) | MXPA03003699A (ko) |
NO (1) | NO329352B1 (ko) |
NZ (1) | NZ525418A (ko) |
PT (1) | PT1328285E (ko) |
RU (1) | RU2275218C2 (ko) |
SE (1) | SE0003907D0 (ko) |
SK (1) | SK287572B6 (ko) |
WO (1) | WO2002034279A1 (ko) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001098335A2 (en) * | 2000-06-20 | 2001-12-27 | Phycotransgenics, Llc | Transgenic algae for delivering antigens to an animal |
US6932980B1 (en) * | 2001-01-18 | 2005-08-23 | Richard Sayre | Method of making microalgal-based animal foodstuff supplements, microalgal-supplemented animal foodstuffs and method of animal nutrition |
US20050267091A1 (en) * | 2004-05-25 | 2005-12-01 | Roger Berlin | Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses |
DE102004043945A1 (de) * | 2004-09-11 | 2006-03-30 | Henkel Kgaa | Mund-, Zahn- und Zahnprotesenpflegemittel enthaltend die Plaquebildung inhibierende Substanzen |
EA011286B1 (ru) * | 2007-08-29 | 2009-02-27 | Общество С Ограниченной Ответственностью "Вдс" | Таблетка для профилактики и лечения заболеваний зубов и пародонта |
FR2931071B1 (fr) * | 2008-05-14 | 2010-08-13 | Roquette Freres | Confiserie aux algues pour la prevention des infections buccodentaires |
US20100183523A1 (en) * | 2009-01-22 | 2010-07-22 | Wagner Richard E | Dental composition and method |
EP2210582B1 (en) * | 2009-01-22 | 2019-09-18 | Solarvest Bioenergy Inc. | Dental composition comprising algae and method for producing thereof |
FR2968558B1 (fr) | 2010-12-14 | 2013-03-22 | Ys Lab | Composition a base d'extrait d'algues a usage bucco-dentaire |
US8916179B2 (en) * | 2011-10-25 | 2014-12-23 | T.F.H. Publications, Inc. | Ascophyllum nodosum animal chews |
CN103877195A (zh) * | 2013-11-15 | 2014-06-25 | 东南大学 | 一种用于治疗肾结石的中药配方组成及其服用方法 |
US20200305440A1 (en) * | 2019-03-27 | 2020-10-01 | UPL Corporation Limited | Plant treatment composition and method |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56117777A (en) * | 1980-02-15 | 1981-09-16 | Takanori Koshiro | Diuretic health food |
JPS56113269A (en) * | 1980-02-15 | 1981-09-07 | Takanori Koshiro | Healthful food for promoting urination |
FR2513122A1 (fr) * | 1981-09-23 | 1983-03-25 | Goemar Sa | Nouveaux medicaments a base d'extraits d'algues, et formulations correspondantes |
US4775525A (en) * | 1985-12-16 | 1988-10-04 | Ivo Pera | Oral hygiene formulation containing sodium alginate |
JP2691902B2 (ja) * | 1988-01-19 | 1997-12-17 | 日本製粉株式会社 | グルコシルトランスフェラーゼ阻害剤及びう蝕予防口腔用組成物 |
GB8803157D0 (en) | 1988-02-11 | 1988-03-09 | Nat Res Dev | Denture protection |
US4857331A (en) * | 1988-03-31 | 1989-08-15 | Warner-Lambert Company | Sugarless pectin delivery system |
JP3013060B2 (ja) * | 1991-11-16 | 2000-02-28 | 株式会社ロッテ | 虫歯菌歯牙付着阻害及び脱離のための口腔用組成物 |
DE4219360C2 (de) * | 1992-06-12 | 1994-07-28 | Milupa Ag | Verfahren zur Gewinnung von Lipiden mit einem hohen Anteil von langkettig-hochungesättigten Fettsäuren |
US6255296B1 (en) * | 1994-01-11 | 2001-07-03 | Endomatrix, Inc. | Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease |
GB2292146A (en) * | 1994-08-11 | 1996-02-14 | Merck & Co Inc | HIV protease inhibitors useful for the treatment of AIDS |
EP1007077B1 (en) * | 1997-01-13 | 2009-10-07 | Emory University | Glutathione for the treatment of influenza infection |
US6338856B1 (en) * | 1998-02-27 | 2002-01-15 | Texas Tech University | Seaweed supplement diet for enhancing immune response in mammals and poultry |
US6224871B1 (en) * | 1998-03-11 | 2001-05-01 | Reliv International, Inc. | Dietary supplement for nutritionally promoting healthy joint function |
GB9819530D0 (en) * | 1998-09-09 | 1998-10-28 | Smithkline Beecham Plc | Novel compositions and use |
JP4189620B2 (ja) * | 2000-03-01 | 2008-12-03 | ライオン株式会社 | 歯周疾患予防・治療用口腔用組成物 |
-
2000
- 2000-10-27 SE SE0003907A patent/SE0003907D0/xx unknown
-
2001
- 2001-09-27 NZ NZ525418A patent/NZ525418A/en not_active IP Right Cessation
- 2001-09-27 PT PT01970473T patent/PT1328285E/pt unknown
- 2001-09-27 ES ES01970473T patent/ES2260286T3/es not_active Expired - Lifetime
- 2001-09-27 DK DK01970473T patent/DK1328285T3/da active
- 2001-09-27 MX MXPA03003699A patent/MXPA03003699A/es active IP Right Grant
- 2001-09-27 AU AU2001290473A patent/AU2001290473A1/en not_active Abandoned
- 2001-09-27 JP JP2002537330A patent/JP4648611B2/ja not_active Expired - Lifetime
- 2001-09-27 CA CA002426936A patent/CA2426936C/en not_active Expired - Lifetime
- 2001-09-27 EP EP01970473A patent/EP1328285B1/en not_active Expired - Lifetime
- 2001-09-27 RU RU2003115613/15A patent/RU2275218C2/ru active
- 2001-09-27 DE DE60117824T patent/DE60117824T2/de not_active Expired - Lifetime
- 2001-09-27 CN CNB018180337A patent/CN1230195C/zh not_active Expired - Lifetime
- 2001-09-27 KR KR1020037005794A patent/KR100890723B1/ko active IP Right Grant
- 2001-09-27 AT AT01970473T patent/ATE319463T1/de active
- 2001-09-27 WO PCT/SE2001/002083 patent/WO2002034279A1/en active IP Right Grant
- 2001-09-27 US US10/399,770 patent/US7125555B2/en not_active Expired - Lifetime
- 2001-09-27 BR BR0114933-4 patent/BRPI0114933B8/pt not_active IP Right Cessation
- 2001-09-27 SK SK506-2003A patent/SK287572B6/sk not_active IP Right Cessation
-
2003
- 2003-04-23 IS IS6795A patent/IS2288B/is unknown
- 2003-04-23 NO NO20031808A patent/NO329352B1/no not_active IP Right Cessation
-
2006
- 2006-06-01 CY CY20061100693T patent/CY1105379T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2426936C (en) | 2009-08-25 |
BRPI0114933B1 (pt) | 2018-05-29 |
US20040022806A1 (en) | 2004-02-05 |
EP1328285B1 (en) | 2006-03-08 |
CA2426936A1 (en) | 2002-05-02 |
DE60117824T2 (de) | 2006-11-02 |
SK287572B6 (sk) | 2011-03-04 |
RU2275218C2 (ru) | 2006-04-27 |
CN1230195C (zh) | 2005-12-07 |
NO329352B1 (no) | 2010-10-04 |
JP4648611B2 (ja) | 2011-03-09 |
PT1328285E (pt) | 2006-07-31 |
SE0003907D0 (sv) | 2000-10-27 |
EP1328285A1 (en) | 2003-07-23 |
AU2001290473A1 (en) | 2002-05-06 |
DE60117824D1 (de) | 2006-05-04 |
IS6795A (is) | 2003-04-23 |
BRPI0114933B8 (pt) | 2021-05-25 |
SK5062003A3 (en) | 2003-08-05 |
WO2002034279A1 (en) | 2002-05-02 |
BR0114933A (pt) | 2004-01-06 |
DK1328285T3 (da) | 2006-07-17 |
ES2260286T3 (es) | 2006-11-01 |
MXPA03003699A (es) | 2003-08-07 |
JP2004512309A (ja) | 2004-04-22 |
KR100890723B1 (ko) | 2009-03-26 |
IS2288B (is) | 2007-10-15 |
CN1471403A (zh) | 2004-01-28 |
US7125555B2 (en) | 2006-10-24 |
ATE319463T1 (de) | 2006-03-15 |
CY1105379T1 (el) | 2010-04-28 |
NO20031808D0 (no) | 2003-04-23 |
NZ525418A (en) | 2004-11-26 |
NO20031808L (no) | 2003-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8496913B2 (en) | Compressed chewing gum tablet | |
Box | Treatment of the periodontal pocket | |
KR100890723B1 (ko) | 플라그 및 결석의 감소를 위한 해초를 함유하는 경구제제 | |
US20090269288A1 (en) | Black pearl toothpaste | |
Anand | Herbal therapy in periodontics: a review | |
Maden et al. | The Efficacy of Xylitol, Xylitol-Probiotic and Fluoride Dentifrices in Plaque Reduction and Gingival Inflammation in Children: A Randomised Controlled Clinical Trial. | |
CN112236148A (zh) | 口腔疾病预防或治疗用组合物 | |
KR20200050801A (ko) | 유게놀 및 죽염을 유효성분으로 포함하는 구강 위생 조성물 | |
US11564878B2 (en) | Oral care product formulation | |
JPH01502111A (ja) | 口腔衛生用医薬 | |
EP1683547A1 (en) | Anticaries toothpaste containing Rubus Fruticosus for treating and cleaning teeth and/or gums | |
KR0179523B1 (ko) | 치은염 치료용 유향과 창출 추출물 함유 치약조성물 | |
Kiruthika et al. | A Review on Herbal Toothpaste for Plaque and Gingivitis | |
KR102275526B1 (ko) | 구강 관리용 치약 | |
Rodriguez et al. | Effects of a Novel Mouthwash on Plaque Presence and Gingival Health | |
Abrol et al. | Efficacy of 2% cymbopogon citratus (lemongrass) gel as an adjunct to scaling and root planing-a clinical study based on phytoscience | |
Teixeira | Holistic approaches to treating periodontal disease | |
Bansal et al. | Oil Pulling: A Natural Cure to Oral Diseases | |
KR20000060197A (ko) | 구강 청정용 조성물 | |
Selbee | Activated charcoal; too abrasive? | |
KR20230037956A (ko) | 구강 내 항균 작용, 잇몸 질환 원인균 억제, 잇몸 질환 예방 및 치료에 유효한 석유황과 쑥 엑스를 유효성분으로 함유하는 기능성 치약 조성물 | |
Pradeep et al. | Short Term Clinical Effects of a Herbal-based Toothpaste: A Randomized Controlled Clinical Trial | |
WO2024064959A2 (en) | Oral care compositions comprising geranylgeraniol and methods of use thereof | |
Trieger | The surgical treatment of periodontal infections | |
JP2022167951A (ja) | 口腔疾患の予防又は治療用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130221 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140221 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150226 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160310 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170313 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180226 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190226 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20200226 Year of fee payment: 12 |